Metastasis-associated mutations in clear cell renal cell carcinoma. This is an ASCO Meeting Abstract from the 2016 Genitourinary Cancers Symposium. This abstract does not include a full text component ...

Prescriber treatment patterns for tyrosine kinase inhibitors (TKI) and mammalian target of rapamycin (mTOR) inhibitors in patients with renal cell carcinoma.

Immunotherapy with immune checkpoint inhibitors is standard first-line treatment for advanced renal cell carcinoma (RCC), but not every patient responds.

In an observational study of second-line therapies for metastatic RCC, overall survival and time-to-treatment failure data favored cabozantinib. A European analysis of second-line therapies for ...